In light of the growing demand for drug delivery solutions, the international technology group SCHOTT is again investing in its pharma business: the company is planning to build an entirely new production for high-quality pre-fillable glass syringes (PFS) in Hungary.
“The added capacity will greatly benefit the global market and strengthen supply security for major pharmaceutical companies and contract manufacturing organizations,” said Andreas Reisse, Executive Vice President of SCHOTT’s Pharma business unit. The double-digit million Euro amount is supported by the local government with about EUR nine million (HUF 3,321 billion). The expansion is scheduled for completion in 2024 and is designed to create 120 new jobs.
The drug containment and delivery solution is an integral part of every medication. Typically, a new drug enters the market in a vial and a single-use syringe is used to extract and administer it. In the mid-to-long term, these drugs may be stored in syringes that are pre-filled with the medication. This simplifies the injection process for healthcare workers and increases dosing accuracy for the patient, as the syringe is already prepared.
“High-quality pre-fillable syringes are designed to ease the administration process, ultimately enhancing patient safety,” explained Christian Helbig, Head of Glass Syringes at SCHOTT’s Pharma business unit. “Our borosilicate glass PFS are used to safely store a wide range of drugs, including vaccines and biologics.”
Already today, SCHOTT’s Hungarian site in Lukácsháza plays an important role in supplying the global industry with drug containment systems and provides enough space for further capacity expansions to follow.
Building on the strong existing foundation and skill set, the production will be equipped with state of the art machinery. As part of SCHOTT’s global production network in 13 countries, the manufacturing will follow high-end processes and advanced quality assurance.